Further studies are needed to determine the long-term effects nicotine may have in patients with Alzheimer's disease. In addition, one must consider the risks of using a chemical that is considered a health hazard to treat a patient with Alzheimer's disease. It would be beneficial to develop a compound similar to but less toxic than nicotine to study and possibly treat patients with Alzheimer's disease. Until alternatives are developed, a trial of nicotine administered transdermally may provide hope and a greater understanding of Alzheimer's disease.